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COMMENTARY
Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal 
disease and gonorrhoea in an infant, child and adolescent program: protocol
Helen S. Marshalla,b,c, Prabha H. Andraweeraa,b,c, Bing Wanga,b,c, Mark McMillan a,b,c, Ann P. Koehlerd, Noel Lallyd, 
Sara Almondd, Emma Denehyd, Michele A’Houred, Lynne C. Gilesb,e, and Louise Flood d
aVaccinology and Immunology Research Trials Unit, Women’s and Children’s Hospital, SA Health, Adelaide, Australia; bRobinson Research Institute, 
The University of Adelaide, Adelaide, Australia; cAdelaide Medical School, The University of Adelaide, Adelaide, Australia; dCommunicable Disease 
Control Branch, SA Health, Adelaide, Australia; eSchool of Public Health, The University of Adelaide, Adelaide, Australia
ABSTRACT
Invasive meningococcal disease causes significant morbidity and mortality worldwide, with serogroup 
B being one of the predominant serogroups in Australia for many years. The South Australian (SA) State 
Government recently funded the introduction of a 4CMenB vaccination program for infants, children and 
adolescents. In addition to protecting against invasive meningococcal disease, emerging evidence 
suggests the 4CMenB vaccine may also be effective against gonorrhoea due to genetic similarities 
between Neisseria meningitidis and Neisseria gonorrhoeae. The proposed project aims to evaluate the 
effectiveness of the SA 4CMenB vaccination program against invasive meningococcal disease and gonor-
rhoea through a combination of observational studies using routine surveillance and research data. The 
main methodological approaches involve an interrupted time series regression model, screening, and 
case-control analyses with different sets of controls to estimate vaccine impact and effectiveness. These 
analyses are designed to minimize potential biases inherent in all observational studies and to provide 
critical data on the effectiveness of the 4CMenB vaccine against two diseases of major global public health 
concern.
ARTICLE HISTORY 
Received 24 June 2020  
Revised 25 August 2020  
Accepted 20 September 2020 
KEYWORDS 




Neisseria meningitidis infection causes significant morbidity and 
mortality worldwide with approximately 500,000–1,200,000 cases 
and 50,000–135,000 deaths reported annually.1,2 Twelve different 
meningococcal capsular groups have been recognized, of which 
six serogroups (A, B, C, W, X and Y) are responsible for most 
cases of invasive meningococcal disease (IMD). Although IMD is 
uncommon, it is still one of the commonest infectious causes of 
death in childhood in many developed countries.3 Meningococcal 
disease usually presents as meningitis or septicemia, potentially 
resulting in septic shock and meningitis with sequelae of neuro-
logical deficits. A recent systematic review and meta-analysis 
representing 163,759 patients with IMD demonstrated a case 
fatality rate between 4.1% and 20.0%.4 Regional variations in 
disease epidemiology have been reported with group B (MenB) 
accounting for a large majority of cases in Europe, the Americas 
and the Western Pacific and groups A (MenA), C (MenC), 
W (MenW) and X (MenX) accounting for a substantial propor-
tion of cases in Africa and Latin America.5 The four most com-
mon meningococcal serogroups causing disease in Australia are B, 
C, W and Y with MenB predominating in South Australia (SA) 
over the last decade In 2018 in SA, a total of 34 cases of IMD were 
notified and of these 27 (79%) were due to group B.6 Similar to 
many countries, the incidence of IMD in Australia is highest in 
children under the age of 5 years (4.6 per 100,000), followed by 
adolescents aged between 15 and 19 years (2.6 per 100,000).7
A meningococcal B vaccine, (4CMenB,Bexsero ®) was first 
licensed for use in Europe in January 2013, and is now 
licensed in Australia, Canada and the United States of 
America. In Australia, the vaccine is recommended for use 
in persons ≥ 6 weeks of age for the prevention of invasive 
disease caused by group B meningococci. Another menin-
gococcal B vaccine (Trumenba®) is also approved in 
Australia for individuals ≥ 10 years of age.8 Commencing 
from July 2020, the 4CMenB vaccine is funded on the 
National Immunization Program (NIP) in Australia for 
Aboriginal and Torres Strait Islander children up to two 
years of age due to their increased risk of meningococcal 
disease but not for other age groups. The SA Government 
introduced the 4CMenB vaccine to the SA State Immunization 
schedule in October 2018.9 As part of the SA program, 4CMenB 
vaccine is provided free to children and adolescents who are 
residents of SA. The United Kingdom (UK) was the first country 
to introduce the 4CMenB vaccine into a publicly funded NIP in 
2015.10 As part of the UK program, a three-dose schedule was 
offered to infants at 2 months, 4 months and 12 months of age. 
This schedule was shown to be highly effective in preventing 
MenB disease in infants, with cases in vaccine eligible infants 
being halved in the first 10 months of the program and recent 
data showing persistence of protection.10,11 Emerging evidence 
suggests the 4CMenB vaccine may offer some protection against 
gonorrhoea.12
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Gonorrhoea, caused by the bacterium N. gonorrhoeae, is 
a sexually transmissible infection (STI) which can infect the 
urethra, cervix, rectum, conjunctiva, and throat. Untreated 
infection can lead to pelvic inflammatory disease, tubal scar-
ring and infertility in females, and swelling and scarring in the 
epididymis or testicles in males. Infection is largely asympto-
matic in women (80%) and in men (50%) and increases the 
chances of acquiring and transmitting HIV.13 Notifications of 
gonococcal infection in Australia have more than tripled in the 
past 10 years from 36 to 134 per 100,000 population (2008 
versus 2019) with re-infection occurring commonly.14
Evidence for a protective effect of a meningococcal vaccine 
against gonorrhoea was first reported in Cuba, with a rapid 
decline in the incidence of gonorrhoea following a vaccination 
campaign with VA-MENGOC-BC from December 1988 to 
December 1990.15,16 Subsequently, it was shown that the 
MeNZB OMV vaccine introduced in New Zealand in 2004 
was also associated with reduced risk of gonorrhoea in adoles-
cents and adults aged 15–30 years over a 10 year follow-up 
period.12 Further evidence comes from a recent study con-
ducted in Quebec, Canada that analyzed the cases of gonor-
rhoea notifications during pre and post vaccination periods of 
a targeted 4CMenB immunization program for those aged 
6 months to 20 years.17 A decline in gonorrhoea notifications 
of 59% among individuals aged 14–20 years was observed 
during the post vaccination period whereas the notifications 
increased in those 21 years and older but confidence intervals 
were wide (95% CI: −22% to 84%; p = .1) due to the small case 
numbers (average 22 per year).17 The authors hypothesized 
that cross-protection occurred despite the difference in disease 
manifestation, because N. meningitidis and N. gonorrhoeae 
share 80–90% genetic homology in primary sequences.18 
Also, recently presented data show high levels of anti- 
gonococcal antibodies generated in adults vaccinated with 
4CMenB, which may explain the suggested cross-protection 
against gonorrhoea.19
In the absence of randomized controlled trials evaluating 
the effectiveness of the 4CMenB vaccine against IMD and 
gonorrhoea, the goal of this evaluation protocol is to undertake 
well designed observational studies to estimate the effectiveness 
of the 4CMenB vaccine against both IMD and gonorrhoea.
Methods and analyses
The South Australian 4CMenB vaccine strategy
The 4CMenB childhood program in SA commenced on 
01 October 2018. Infants aged 6 weeks to 12 months receive 
three doses of the vaccine, administered at 6 weeks, 4 and 
12 months of age which aligns with the usual schedule points 
for NIP vaccines. A time limited childhood catch-up program, 
for children aged 12 months to less than 4 years at the com-
mencement of the program, offers two doses of the vaccine in 
total, administered with a minimum dose interval of two 
months.
The adolescent 4CMenB program is offered through 
a School Immunization Program and commenced on 
01 February 2019. Students in year 10 receive two doses of 
the vaccine administered with a minimum dose interval of two 
months. A catch-up program is available for those in year 11 
(aged approximately 15–16 years) in 2019, and for those who 
were aged 17 to less than 21 years of age at the commencement 
of the program. The time limited catch-up program offers two 
doses of the vaccine administered with a minimum dose inter-
val of two months. In addition to the adolescent program, 
34,486 students in years 10, 11 and 12 in SA received the 
4CMenB vaccine as part of the Meningococcal B Vaccine 
Herd Immunity Study (B Part of It Study) in 2017 and 
2018.20,21
Objectives of the evaluation
The primary objective of the planned evaluation is to estimate 
the effect of the 4CMenB program (vaccine impact and effec-
tiveness) for infants and adolescents against IMD over a -
three year period. The secondary objectives are to: a) estimate 
the number of potential 4CMenB vaccine failures in the infant 
and adolescent programs; b) estimate the effect of the adoles-
cent 4CMenB program (vaccine impact and effectiveness) 
against gonorrhoea; and c) evaluate the cost effectiveness of 
the 4CMenB vaccination program. We hypothesize that vacci-
nated cases will have reduced rates of serious complications/ 
sequelae compared to unvaccinated cases. Hence, the severity 
of IMD and sequelae of IMD among cases pre and post imple-
mentation of the SA 4CMenB vaccination program (based on 
vaccination status of the case)will also be evaluated.
Data collection
IMD and gonorrhoea are both notifiable diseases under the 
South Australian Public Health Act 2011. Consequently, all 
cases of suspected and confirmed IMD and gonorrhoea in SA 
are reported to the Communicable Disease Control Branch 
(CDCB), South Australian Government Department of 
Health and Wellbeing (SA Health), by medical practitioners 
and diagnostic laboratories.
SA Pathology provides laboratory results on culture and/or 
PCR positivity, genogroup and serogrouping for IMD. Any avail-
able meningococcal isolates undergo whole genome sequencing 
(WGS) with multi-locus sequence type (MLST) and fine typing.
The Australian Immunization Register (AIR) is the popula-
tion-based register of residents enrolled in the national publicly 
funded health care system, Medicare, regardless of vaccination 
status (99% enrollment of all Australian children by 12 months 
of age). Vaccine providers report administered vaccines to the 
AIR. In addition, from the commencement of the 2019 
school year, contracted school immunization providers in SA 
enter all school immunizations on the Immunization Records 
and Inventory System (IRIS). Data from IRIS are routinely 
transferred to the AIR. Vaccine uptake data will be obtained 
through AIR. It is not mandatory to enter 4CMenB immuniza-
tion data in the AIR. Therefore, there will be some under 
reporting but it is likely to be minimal.
Vaccine safety is routinely monitored through SA Health’s 
Vaccine Safety Surveillance (SAVSS) system, an enhanced pas-
sive surveillance system of adverse events following immuniza-
tion (AEFI). Data on any AEFI will be available through 
SAVSS.
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Disease severity during pre and post 4CMenB vaccination 
program introduction will be assessed using data from the 
Integrated South Australian Activity Collection (ISAAC), the 
PAEDS (Pediatric Active Enhanced Disease Surveillance) and 
the AMEND (Adolescent MENingococcal Disease) study. 
Hospital separation data on length of hospital stay, require-
ment for intensive care unit (ICU) admission and length of stay 
in ICU will be obtained from ISAAC. Data on IMD cases 
among children will be obtained from PAEDS. The PAEDS 
network is a hospital-based active surveillance system employ-
ing prospective case ascertainment for selected serious child-
hood conditions, particularly vaccine preventable diseases 
including IMD, and potential AEFI.22 Data on IMD cases 
among 15–24 year olds will be obtained from the AMEND 
study.23 The AMEND study is a multi-center case control study 
currently conducted in Australia with the aim of identifying 
long term clinical, physical, neurocognitive, economic and 
societal impact of IMD on adolescents and young adults.
Statistical analyses
Evaluation of 4CMenB vaccine impact against IMD
Vaccine impact on IMD will be estimated using state surveil-
lance data from CDCB for laboratory confirmed MenB cases, 
comparing six pre-vaccine surveillance years to the post vacci-
nation period, annually for three years for the childhood and 
the adolescent programs after introduction of 4CMenB vac-
cine. Interrupted time series analysis will be used to compare 
the number of cases observed to the number of cases predicted 
if the pre-vaccine trends continued in the post vaccination 
period.24 To estimate impact in each vaccine eligible group, 
incidence rate ratios will be estimated by comparing case 
numbers in each post vaccination surveillance year with cases 
in the equivalent cohort during the six pre-vaccination years. 
To take into account any changes over time unrelated to MenB 
vaccination, the incidence rate ratios will be adjusted using in 
the relevant annual MenB incidence in all children/adolescents 
who were not in the vaccine-eligible cohorts.
Evaluation of 4CMenB vaccine effectiveness (VE) against 
IMD
Screening method. VE will be estimated for vaccine-eligible 
infants/adolescents under the program with onset of 
laboratory confirmed IMD within the first post vaccine 
implementation year and for each calendar year afterward. 
For cases, vaccine doses (≥ 2 doses for infants and 2 doses 
for adolescents and for children 12 months to less than 
4 years who are eligible to receive the vaccine as part of 
the catch up program) will be counted if disease onset 
occurred ≥ 14 days after the dose. This 14-day period 
allows for an immune response post vaccination. The 
comparator group will include all children and adolescents 
who are eligible for the MenB vaccine program in SA. VE 
will be estimated as where PCV is the proportion of 
vaccinated MenB cases and PPV is the age-specific vaccine 
coverage.25 In order to use this age and period matched 
coverage for each case, a logistic regression model will be 
fit with vaccination status of each case as the exposure. VE 
will be calculated as 1 minus the odds ratio estimated 
from the model. VE will be estimated in this way for 
each age group in the vaccine program.
Case control method. Confirmed cases of IMD in each age 
cohort will be obtained from CDCB. For the purpose of asses-
sing vaccine effectiveness, we will include only cases eligible for 
vaccination under the state MenB vaccine program.
At least 20 controls will be randomly sampled for each case 
from a de-identified dataset of individual records extracted 
from the AIR, following restriction of the database to SA. As 
the analysis relies on discordance in vaccination status 
between cases and matched controls, ≥ 20 controls for each 
case will be selected from AIR, this database provides 
a readily available source of controls. In addition, a previous 
similar study that assessed the effectiveness of the varicella 
vaccine in Australia demonstrated maximum precision using 
20 controls per case.26 Controls will be matched to cases by 
date of birth (± 28 days).Vaccination status of controls will be 
ascertained from the AIR after selection and vaccination 
considered valid if received ≥ 14 days before the date of 
disease onset in the matched case. This method of control 
ascertainment has been used previously to assess VE of 
Haemophilus influenzae serotype B, pertussis, varicella and 
measles vaccines in Australia.26 Conditional logistic regres-
sion models, explicitly recognizing each stratum of cases and 
controls will be generated to estimate VE.
Estimation of potential vaccine failures
All cases of IMD in children, adolescents and young adults < 
25 years of age reported to CDCB will be investigated for prior 
vaccination with 4CMenB and timing since vaccination. 
Clinical history will be obtained to determine any underlying 
risk factors. Causative genogroups will be identified from blood 
culture and/or cerebrospinal fluid, in accordance with usual 
clinical practice. Where an isolate is not available (PCR only), 
informed consent will be sought and a throat swab taken to aid 
in identification of the causative organism. Determination of 
whether a case should have been prevented by vaccination (i.e. 
vaccine antigens identified in the isolate) is important in deter-
mining true vaccine failures as distinct to those cases where 
disease arose from isolates that do not carry the vaccine 
antigens.
Isolates will undergo whole genome sequencing to identify 
vaccine antigens using the Bexsero® Antigen Sequence Type 
(BAST) scheme to assess likelihood of coverage by 4CMenB 
vaccine using the PubMLST database. In addition, isolates will 
be transferred to the Public Health England Vaccine 
Evaluation Unit, Manchester, United Kingdom to undergo 
MATS testing to identify the likelihood of coverage of the 
isolate by 4CMenB vaccine.27 The Meningococcal Antigen 
Typing System (MATS) was developed to identify MenB 
strains with a high likelihood of being covered by 4CMenB.28 
Results of MATS testing of isolates during the period 
January 2007-June 2011 suggest that 4CMenB vaccine will 
cover 90% of MenB strains causing disease in SA.29 This 
provides a more nuanced interpretation of vaccine coverage, 
providing estimates of the presence of vaccine antigen and 
expression.
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Evaluation of 4CMenB vaccine impact and effectiveness 
against gonorrhoea
Laboratory confirmed cases of gonorrhoea will be obtained 
from CDCB. Similar methods as described for assessment 
of 4CMenB impact and effectiveness against IMD will be 
undertaken to assess the impact and effectiveness of the 
vaccine against gonorrhoea in adolescents. Two separate 
analyses will be conducted in the evaluation of vaccine 
effectiveness, with (1) controls randomly selected from 
AIR and (2) from the SA notifiable disease database for 
chlamydia. Planned statistical analyses are similar to those 
described for IMD.
Evaluation of the cost effectiveness of the 4CMenB 
vaccination program in SA
A decision analytic model will be used to assess the cost- 
effectiveness of the 4CMenB vaccine against IMD and 
gonorrhoea. A systematic review has already been con-
ducted to evaluate the clinical and financial burden of 
IMD.4,30 In addition, a comprehensive systematic review 
of the extant literature will be performed to assess the 
burden of gonorrhoea. This review will be used to identify 
the best model for cost effectiveness analysis. Costs asso-
ciated with the management of these infections will be 
estimated using Australian hospital costing data. These 
estimates will be combined with literature-based estimates 
of the broader costs associated with these infections, as well 
as quality of life and mortality effects to estimate Quality 
Adjusted Life Year gains.31
In the base case, future costs will be discounted to their 
present value at 5% annually and the healthcare system per-
spective will be employed as recommended by Australian 
guidelines.32 Discount rates of 0% and 3.5% will be consid-
ered in sensitivity analyses. The healthcare system perspective 
captures direct medical costs associated with IMD and gonor-
rhoea. The cost-effectiveness analysis will also be performed 
from the societal perspective, including direct healthcare 
costs, direct non-healthcare costs/government subsidies (e.g. 
home modification and special education) and indirect costs 
associated with productivity loss. To estimate indirect costs, 
two approaches will be used: human capital33 and friction 
cost methods.34 The human capital method estimates the 
reduction in gross earnings due to morbidity and/or prema-
ture mortality.31 The friction cost method only considers the 
time span employers need to restore the initial production 
level.35
Comparison of the severity of IMD and sequelae of IMD 
among cases pre and post implementation of the SA 
4CMenB vaccination program
Data on severity and sequelae of IMD cases during the three 
post- vaccination surveillance years will be compared with 
those of the six years preceding the implementation of the 
program. Data for these descriptive analyses will be obtained 
from ISAAC, PAEDS and the AMEND Study.
Discussion
A State funded MenB immunization program is now available 
for infants, children, adolescents and young people, in the most 
extensive funded MenB vaccine program globally. It is 
expected that the majority of disease-causing MenB strains in 
SA express at least one of the vaccine antigens, which would 
make them susceptible to effective killing by vaccine-induced 
antibodies. In the absence of a randomized controlled trial, to 
evaluate the effectiveness of the 4CMenB vaccine against IMD, 
the proposed suite of observational studies will provide 
a comprehensive evaluation of the newly introduced MenB 
vaccination program in SA. Emerging evidence additionally 
suggests a protective effect of the 4CMenB vaccine against 
gonorrhoea. Therefore, the proposed evaluation presents 
a unique opportunity to confirm the findings from studies 
conducted in New Zealand and Canada, in the Australian 
population. Overall, the results will be important in providing 
vital information to guide future policy decisions and inform 
the cost effectiveness of the SA program. These results will also 
have international significance for other countries considering 
implementation of a MenB vaccine program.
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